Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
new york blog main
3
×
boston blog main
boston top stories
drugs
national top stories
new york
new york top stories
san diego blog main
san diego top stories
achaogen
adams street partners
akcea therapeutics
amgen
antibiotics
anylam pharmaceuticals
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech
cardiomyopathy
cholesterol
data
deals
drug resistance
fda
hatteras venture partners
inclisiran
inotersen
investing
ldl
lyzz capital
macrolide pharmaceuticals
mark timney
melinta therapeutics
meropenem
michael dudley
mt sinai hospital
neuropathy
What
drug
3
×
medicines
3
×
year
3
×
disease
aces
ago
akcea
alnylam
amyloidosis
announced
approved
attr
available
bacteria
battle
big
biopharma
business
ceo
cholesterol
company
debilitating
exited
fda
fighting
flexible
genetic
inclisiran
infections
infectious
key
launches
lowering
meant
medco
medicine
melinta
nasdaq
oks
open
Language
unset
Current search:
drug
×
year
×
" new york blog main "
×
medicines
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections